

**FILE COPY**

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	1	<b>Complete if Known</b>	
				Application Number	09/323,854
				Filing Date	June 2, 1999
				First named Inventor	TAM
				Group Art Unit	1647
				Examiner Name	David S. Romeo
				Atty Docket Number	46913/00047

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
PR	A1	4,320,118		White et al.	03/16/1982	
	A2	4,877,864		Wang et al.	10/31/1989	
	A3	4,897,348		Johnston et al.	01/30/1990	
	A4	5,011,691		Oppermann et al.	04/30/1991	
	A5	5,024,841		Chu et al.	06/18/1991	
	A6	5,264,214		Rhee et al.	11/23/1993	
	A7	5,354,557		Oppermann et al.	10/11/1994	
	A8	5,461,034		Rodan et al.	10/24/1995	
	A9	5,470,911		Rhee et al.	11/28/1995	
	A10	5,578,569		Tam	11/26/1996	
	A11	5,661,127		Bhatnagar et al.	08/26/1997	
	A12	5,786,327		Tam	07/28/1998	
	A13	5,880,094		Tam	03/09/1999	
	A14	6,274,702		Tam	08/14/2001	
PR	A15	6,352,973		Tam	03/05/2002	
	A16					

**FOREIGN PATENT DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
PR	B1	WO	WOA90/00060			01/01/1990		
	B2	WO	WO90/06321			06/14/1990		
	B3	WO	WO91/11515			08/08/1991		
	B4	EP	0451867			10/16/1991		
	B5	UK	2231872			07/22/1992		
	B6	EP	0499242			08/19/1992		
	B7	WO	WO92/14481			09/03/1992		
	B8	EP	0504938			09/23/1992		
	B9	WO	WO94/05309			03/17/1994		
	B10	WO	WO94/20615			09/15/1994		
PR	B11	WO	WO95/28172			10/26/1995		

Examiner  
Signature*David S. Romeo*Date  
Considered

4/3/3

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/323,854
				Filing Date	June 2, 1999
				First named Inventor	TAM
				Group Art Unit	1647
				Examiner Name	David S. Romeo
Sheet	1	of	3	Atty Docket Number	46913/00047



### OTHER DOCUMENTS


Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s) publisher, city and/or country where published	T <sup>2</sup>
<del>NO DATE</del>	<del>C1</del>	<del>TAM et al., "Bone Biopsy in the Diagnosis of Primary ... " Endoc. Calc. Metab. Excerpta Med. 427 (Abstract).</del>	
DR	C2	SELYE, "On the Stimulation of New Bone-Formation . . . " Endocrinology 16: 547-558 (1933).	
	C3	AITKEN et al. "Primary Hyperparathyroidism with Osteosclerosis . . . " Am. J. Med. 37: 813-820 (Nov. 1964).	
	C4	KALU et al., "Parathyroid Hormone and Experimental . . . " Lancet 1363-1366 (Jun. 1970).	
	C5	KLEIN et al., "Prostaglandins: Simulation of Bone Resorption . . . " Endocrinology 86: 1436-14 1440 (Jun. 1970).	
	C6	CONNOR et al., "Generalized Osteosclerosis in Primary . . . " Trans Am. Clin. Climato. Assoc. 85: 185-201 (1973).	
	C7	GENANT, "Osteosclerosis in Primary Hyperparathyroidism" Am. J. Med. 59: 104-113 (Jul. 1975).	
	C8	RUDINGER et al. Peptide Hormones. Parsons, eds., University Park Press, Baltimore, pp. 1-7, 1976.	
	C9	TAM et al., "Bone Apposition Rate as an Index of . . . " Metabolism 27(2): 143-150 (Feb. 1978).	
	C10	BEGG et al., "Complete Covalent Structure of Human .beta.-Thromboglobulin", Structure of .beta.-Thromboglobulin, vol. 17, No. 9, 1978, pp. 1739-1744.	
	C11	SCHULZ et al., Principles of Protein Structure, Springer-Verlag, New York, pp. 14-16, 1979.	
	C12	MARKS et al., "The Hematogenous Origin of Osteoclasts: Experimental . . . " Am. J. Anat 161: 1-10 (1981).	
	C13	CHEN, "Glucocorticoid Regulation of 1.25(OH)2-Vitamin D3 . . . " J. Bio. Chem. 257(22): 13564-13569 (Nov. 1982).	
	C14	PARFITT, "The Coupling of Bone Formation to Bone . . . " Metab. Bone Dis. & Rel. Res. 4:1-6 (1982).	
	C15	TAM et al., "Parathyroid Hormone Stimulates the Bone . . . " Endocrinology 110(2): 506-512 (1982).	
	C16	C.W. CASTOR et al., "Structural and Biological Chacteristics of Connective Tissue Activating Peptide (CTAP-III), a Major Human Platelet-3 derived Growth Factor", Proc. Natl. Acad. Sci. USA, vol. 80, Fed. 1983, pp. 765-769.	
	C17	CHYUN, "Stimulation of Bone Formation by Prostaglandin E2" Prostaglandins J. 27(1): 97-103 (Jan. 1984).	
DR	C18	CANALIS, "Effect of Growth Factors on Bone Cell . . . " Clin. Orthop. & Rel. Res. 246-263 (1985).	

Examiner Signature	<i>David S. Romeo</i>	Date Considered	4/3/3
--------------------	-----------------------	-----------------	-------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>	
			Application Number	09/323,854
Sheet 2 of 3			Filing Date	June 2, 1999
			First named Inventor	TAM
			Group Art Unit	1647
			Examiner Name	David S. Romeo
			Atty Docket Number	46913/00047



OTHER DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s) publisher, city and/or country where published	T <sup>2</sup>
AR	C19	DART et al. Transforming growth factors from a human tumor cell: characterization of transforming growth factor beta and identification of high molecular weight transforming growth factor alpha. Biochemistry, (Oct. 8, 1985) 24 (21) 5925-31.	
	C20	OWEN, "Lineage of Osteogenic Cells and Their . . . " Bone & Mineral Res. 3(1):1-25 (1985).	
	C21	SUNDELIN et al, "The Primary Structure of Rabbit and Rat Prealbumin . . . " J. Biol. Chem. 260(10):6481-6487 (May 1985).	
	C22	GEORGE et al., Macromolecular Sequencing and Synthesis: Selected Methods and Applications, Schlesinger, ed., Alan R. Liss Inc., New York, pp. 127-149, 1988.*	
	C23	CASTOR et al., "Connective Tissue Activation--Biologically Active Cleavage Products of CTAP-III From Human Platelets", Biochemical and Biophysical Research Communications, vol. 163, No. 2, 1989, pp. 1071-1078.	
	C24	NODA et al. In vivo stimulation of bone formation by transforming growth factor-beta. Endocrinology, (Jun. 1989) 124(6) 2991-4.	
	C25	TAM, "The Pathogenesis of Metabolic Bone Disease . . . " CRC Press, Boca Raton 2: 19-31 (1989).	
	C26	BOWIE et al. Science 247: 1306-1310, 1990.	
	C27	WALZ et al., "Generation of the Neutrophil-Activating Peptide NAP-2 from Platelet Basic Protein or Connective Issue-3 Activating Peptide III Through Monocyte Proteases", Journal of Med., vol. 171, Feb. 1990, pp. 449-454.	
	C28	WELLS, Biochemistry 29:8509-8517, 1990.*	
	C29	WOZNEY et al., J. Cell. Sci. Suppl. 13:149-156 (1990).	
	C30	CASTOR et al., "Connective Tissue Activation", Arthritis & Rheumatism, vol. 35, No. 7, Jul. 1992, pp. 783-793.	
	C31	ROODMAN, "Perspectives: Interleukin-6: An Osteotropic Factor?" J. Bone & Mineral Res. 7(5): 475-478 (1992).	
	C32	NGO et al. The Protein Folding Problem and Tertiary Structure Prediction. Merz et al, eds., Birkhauser, Boston, pp. 491-495, 1994.	
	C33	VAUGHAN et al., Identification and Characterization of the Insertion Element IS1070 from <i>Leuconostoc lactis</i> NZ6009, Elsevier Science B.V. pp. 95-100 (1995).	
	C34	NAVAB et al., "Rat Plasma Prealbumin" J. Biol. Chem. 252:5100-5106 (Jul. 1997).	
	C35	VAUGHAN et al., U17353, <i>Leuconostoc lactis</i> insertum sequence IS1070: Is1070 putative transposase (tnp) gene, complete cds. 13-SEP-1995.	
AR	C36	Stedman's Medical Dictionary, 27 <sup>th</sup> edition Medical Economics Company, Inc. 2000.	

Examiner Signature	<i>David S. Romeo</i>	Date Considered	4/3/3
--------------------	-----------------------	-----------------	-------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

3

of

3

**Application Number**

09/323,854

Filing Date

June 2, 1999

**First named Inventor**

**TAM**

### Group Art Unit


1647

**Examiner Name**

**David S. Romeo**

**Atty Docket Number**

46913/00047

Examiner  
Initials\*Cite  
No.<sup>1</sup>

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s) publisher, city and/or country where published

 $T^2$  $\Phi R$ 

C37

Abstract – WO 92/10515, PHARMA BISSENDORF PEPTIDE GMBH, Derivatives of the Human Parathormone Fragment (1-37) in the Amide or Ethylamide Form as Active Substance, June 25, 1992.

 $\Phi R$ 

C38

Abstract – WO 92/15615, CHUGAI SEIYAKU KABUSHIKI KAISHA, Serum Calcium Depressing Factor, September 17, 1992.

**Examiner  
Signature**

Harold Barnes

Date \_\_\_\_\_

Considered

4/3/3

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This document is done, be sure to include the last four references.